Haleon plc Profile Avatar - Palmy Investing

Haleon plc

Haleon plc engages in the research and development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides therapeutic oral health, pain r…
Drug Manufacturers - Specialty & Generic
GB, Weybridge [HQ]

FA

Fundamental Analysis · Most Recent Quarter

It is important to understand the FA Algorithm and the criterias before valuing it as a top-tier resource.

Read Rationale
Framework:
Valuation 14% Weak
Profitability n.A. n.A.
Fin. Growth 67% Positive
Leverage & Liquidity n.A. n.A.
Per Share Metrics 0% Bad
Fin. Health n.A. n.A.
1 Financial Health
Metric Q4 Q1 Δ in %
Current Ratio inf 0.00 1.04
Debt/Assets n.A. n.A. n.A.
Debt/Equity n.A. n.A. n.A.
Net Debt/EBITDA -94.41 1.54 27.58
Naive Interpretation member
2 Per Share
Metric Q4 Q1 Δ in %
Book Value -42.44 1.82 3.16
Cash -42.86 0.11 0.20
Capex 0.00 0.00 0.00
Free Cash Flow 0.00 0.00 0.00
Revenue -39.70 0.32 0.53
Naive Interpretation member
3 Profitability
Metric Q4 Q1 Δ in %
Gross Margin 17.60 0.63 0.54
Operating Margin 129.03 0.22 0.10
ROA inf 0.00 < 0.005
ROE 13896.33 0.03 < 0.005
ROIC 6815.55 0.03 < 0.005
Naive Interpretation member
4 Valuation
The "Valuation Entry" for the Focus of HLNCF is permitted for members.
5 Growth
The "Growth Entry" for the Focus of HLNCF is permitted for members.
6 Leverage & Liquidity
The "Leverage & Liquidity Entry" for the Focus of HLNCF is permitted for members.